Oncology Biopharmaceuticals

Bristol-Myers Squibb Company

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

PILL

ARKG

SBIO

CELG.RT

Guggenheim has reaffirmed a "buy" rating for Bristol Myers Squibb (NYSE:BMY) with a price target of $72.00, indicating a potential upside of 24.82%. Other analysts have also raised their price targets, with a consensus rating of "Hold" and an average target of $61.35. The stock opened at $57.68, with a market cap of $117.77 billion. Bristol Myers Squibb reported $1.26 EPS for the last quarter, missing estimates, but revenue was $12.50 billion, exceeding expectations. The company has set FY 2026 guidance at 6.050-6.350 EPS.

Market Beat

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Bristol Myers Squibb

Health Care Select Sector SPDR

VG Health

iShares US Pharma

ProShares Ultra Health Care ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Direxion Pharma & Medical Bull 3X

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

Bristol Myers Squibb (NYSE:BMY) Earns Buy Rating from Guggenheim

Erste Group analyst has maintained a Hold rating on Bristol-Myers Squibb (BMY), with shares closing at $61.73. The overall analyst consensus suggests a Moderate Buy rating with an average price target of $62.67, indicating a potential upside of 1.52%. Additionally, Wells Fargo also assigned a Hold rating with a price target of $60.00.

Tip Ranks

Bristol-Myers Squibb (BMY) Gets a Hold from Erste Group

COCP

In Thursday's intraday session, several health care stocks experienced significant movements. Profusa (NASDAQ:PFSA) surged 48.6% to $0.86, while Cocrystal Pharma (NASDAQ:COCP) rose 45.1% to $1.48. Bristol-Myers Squibb's Celgene Contingent Value Rights (NYSE:CELGR) increased by 35.32% to $0.12. Conversely, Lipocine (NASDAQ:LPCN) plummeted 78.4% to $2.0, and Inovio Pharmaceuticals (NASDAQ:INO) fell 36.9% to $1.1. Overall, the session saw notable gains and losses among various health care stocks.

benzinga_article

Cocrystal Pharma

89BIO INC - CONTINGENT VALUE RIGHT

Profusa

12 Health Care Stocks Moving In Thursday's Intraday Session

In Wednesday's trading session, Cyclerion Therapeutics (CYCN) saw a significant gain of 307.1%, reaching $6.31, while Axe Compute (AGPU) rose by 94.44% to $3.15. Other notable gainers included Regencell Bioscience (RGC) up 39.99% and Cognition Therapeutics (CGTX) up 26.26%. Conversely, ORIC Pharmaceuticals (ORIC) fell 27.3% to $9.21, and Bristol-Myers Squibb's CELGR dropped 26.39%. IO Biotech (IOBT) and BioAtla (BCAB) also experienced declines of 25.9% and 22.24%, respectively. Q4 earnings reports influenced several stock movements.

Regencell Bioscience

IO Biotech

Cyclerion Therapeutics

ORIC Pharmaceuticals

BioAtla

Axe Compute

Cognition Therapeutics

IO BIOTECH INC

12 Health Care Stocks Moving In Wednesday's Intraday Session

Bristol-Myers Squibb Company rose by 26.10%

Price Alert

U.S. stock market quick update: Bristol-Myers Squibb receives FDA approval and analysts raise expectations, stock price surges 26.10%!

Bristol Myers Squibb has received FDA approval for its oral drug Sotyktu to treat adults with active psoriatic arthritis, expanding its immunology portfolio. The approval follows positive results from Phase 3 trials, showing significant disease control compared to placebo. Despite a slight after-hours stock dip, the company emphasizes Sotyktu's role in managing symptoms of psoriatic disease. The drug's safety profile is similar to previous studies, with common side effects including respiratory infections and mouth ulcers. This approval builds on its initial 2022 clearance for moderate-to-severe plaque psoriasis.

Bristol Myers Wins FDA Approval for Sotyktu for Psoriatic Arthritis

In Friday's trading session, Tandem Diabetes Care (TNDM) saw a significant gain of 35% to $25, following its Q4 earnings report, while Bristol-Myers Squibb's Celgene CVR (CELGR) rose 22.21% to $0.11. Other notable gainers included Cardio Diagnostics (CDIO) up 19.64%, enVVeno Medical (NVNO) up 18.11%, and Nasus Pharma (NSRX) up 18%. Conversely, GRAIL (GRAL) experienced a sharp decline of 47.8% to $53.02, with Dermata Therapeutics (DRMA) down 25.86%, and BioRestorative Therapies (BRTX) down 15.75%.

iShares US Medical Devices

CARDIO DIAGNOSTICS HOLDINGS INC C/WTS (10/25/2027) TO PUR COM

Nasus Pharma

Cardio Diagnostics

iShares Global Healthcare

iShares Genomics Immunology and Healthcare ETF

iShares US Healthcare Providers

enVVeno Medical

SPDR S&P Health Equip

Tandem Diabetes

12 Health Care Stocks Moving In Friday's Intraday Session

Bristol-Myers Squibb Company rose 26.36%

U.S. stock market midday update: Bristol-Myers stock price skyrockets 26.36%, trading volume surges, what is driving such high market sentiment?

Bristol-Myers Squibb Company fell by 34.92%

U.S. Stock Market Midday Update: Bristol-Myers Squibb drops 34.92% after a 272.78% increase over six months, volatility attracts market attention

MNTS

Overview of the US Stock Market Recently, the US stock market has shown strong sector rotation, with the technology and pharmaceutical sectors performing particularly well. There seems to be a strong interest in small-cap stocks and thematic stocks, driving significant increases in several stocks. The market pace is fast, volatility has increased, short-term enthusiasm has clearly risen, and investor sentiment is positive. The stock with the largest movement, SMX Security Matters, saw its price soar by 85.74%, with significantly increased trading volume, indicating strong market attention. There is a noticeable influx of funds, driving rapid price increases and heightened short-term sentiment. Strong stocks: 1. Bristol-Myers Squibb Company: up 63.09%, with a five-day increase of 76.00%, the leader in the pharmaceutical sector. 2. Momentus: up 58.14%, with a ten-day increase of 57.15%, a star stock in the technology sector. 3. Monte Rosa Therapeutics: up 49.59%, with a six-month increase of 362.58%, a dark horse in the pharmaceutical field. 4. Regencell Bioscience: up 48.74%, with increased trading volume and heightened market attention. 5. NovaBay Pharmac: up 44.93%, reaching a new 60-day high, showing strong performance in the pharmaceutical sector. 6. Treasure Gbl: up 44.39%, with increased trading volume and noticeable fund inflow

SMX Security Matters

Momentus

Monte Rosa Therapeutics

Novabay Pharmac

Treasure Gbl

Sky Quarry

Ventyx Biosciences

Salarius Pharmaceuticals

Neumora Therapeutics

Cohen

Opendoor Tech Series A - CW26

Ascent Solar Tech

Opendoor Tech Series Z - CW26

374Water

Next Tech

Sable Offshore

Datavault AI

Trident Digital Tech

Opendoor Tech Series K - CW26

Decoy Therapeutics

Stablecoin Development

U.S. stock market movement update: SMX surged 85%, Bristol-Myers rose 63%, Cohen fell 30%, and short-term capital in the market is active

Bristol-Myers Squibb Company(CELG.RT.US)